Liu Xinsheng, Zheng Yaxin, Li Hongtao, Wang Meiyi, You M James, Tian Chen
Yidu Central Hospital, Weifang, China.
Department of Hematology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Oncology. 2023;101(12):822-835. doi: 10.1159/000532090. Epub 2023 Aug 18.
The effect of autologous hematopoietic stem cell transplantation (auto-HSCT) versus conventional chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the survival of patients with advanced follicular lymphoma (FL) is uncertain.
To elucidate this, FL and HSCT were used as keywords to search in PubMed, Embase, Web of Science, and Cochrane Library databases.
After data extraction and quality evaluation, a total of 13 studies were included, seven of which compared auto-HSCT with conventional chemotherapy and the other six compared allo-HSCT with auto-HSCT to the survival of FL patients.
The results showed that auto-HSCT improved overall survival (OS), progression-free survival, and event-free survival of FL patients compared with conventional chemotherapy without auto-HSCT. Compared with allo-HSCT, the patients receiving auto-HSCT had longer OS and lower non-recurrent mortality.
Auto-HSCT can provide a survival advantage for patients with FL compared with conventional chemotherapy and allo-HSCT did not result in a survival benefit.
自体造血干细胞移植（auto-HSCT）与传统化疗或异基因造血干细胞移植（allo-HSCT）相比，对晚期滤泡性淋巴瘤（FL）患者生存的影响尚不确定。
为阐明这一点，以“FL”和“HSCT”作为关键词在PubMed、Embase、Web of Science和Cochrane图书馆数据库中进行检索。
经过数据提取和质量评估，共纳入13项研究，其中7项比较了auto-HSCT与传统化疗，另外6项比较了allo-HSCT与auto-HSCT对FL患者生存的影响。
结果显示，与未进行auto-HSCT的传统化疗相比，auto-HSCT改善了FL患者的总生存期（OS）、无进展生存期和无事件生存期。与allo-HSCT相比，接受auto-HSCT的患者OS更长，非复发死亡率更低。
与传统化疗相比，auto-HSCT可为FL患者提供生存优势，而allo-HSCT未带来生存获益。
